Spring Bank Pharmaceuticals

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

F Star provides IT consulting, system planning and introduction support from the standpoint of financial institutions and customers.  F Star was founded in 2011 and was headquartered in Tokyo, Japan.

F-Star Therapeutics Inc

CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to transform the lives of patients with cancer through the development of innovative tetravalent...

F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals

HOPKINTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Please replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline. The corrected release reads: HOPKINTON, MA, Nov. 19, 2020 – Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) ("Spring...

CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics

1-for-4 Reverse Stock Split to be Effective November 20, 2020 1-for-4 Reverse Stock Split to be Effective November 20, 2020

Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics

HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the receipt of stockholder approval of the Exchange (as defined below) and the reverse stock split, to declare a one-time special dividend on each outstanding share of Spring Bank's common stock, payable on a post-reverse stock split basis following the reverse stock split, in the form of contractual rights to receive, (x) one contingent value right (“STING Agonist CVR”) entitling the holder of each such post-split share of common stock to receive, in connection with certain potential future transactions involving Spring Bank's proprietary STimulator of INterferon Genes (STING) agonist compound designated as SB 11285 occurring on or prior to the STING Agonist CVR Expiration Date (as defined below) that result in certain payments as described below and (y) one contingent value right (“STING Antagonist CVR” and, together with the STING Agonist CVR, the “CVRs”) entitling the holder of each such post-split share of common stock to receive, in connection with the execution of a potential development agreement and certain other transactions involving Spring Bank's proprietary STING antagonist compound occurring on or prior to the STING Antagonist CVR Expiration Date (as defined below) certain payments as described below.

Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights

HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced an upcoming trial-in-progress poster presentation for SB 11285 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020. SB 11285 is Spring Bank's intravenously (IV)-administered STING agonist product candidate that is currently being evaluated in a Phase 1a/1b clinical trial as a monotherapy and in combination with Roche's PD-L1 checkpoint inhibitor (Tecentriq®). This poster presentation will include an update on the progress of the IV SB 11285 Phase 1a/1b trial.

Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) in connection with its merger with F-star Therapeutics Limited. The lawsuit seeks damages and/or equitable relief on behalf of Spring Bank shareholders under the federal securities laws. If you are a Spring Bank shareholder and would like to join the action, visit Spring Bank Class Action or contact Da

Spring Bank Class Action: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spring Bank Pharmaceuticals, Inc.; Investors Are Encouraged to Contact the Firm - SBPH

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (NASDAQ: SBPH) in connection with SBPH's July 29, 2020 merger and...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Spring Bank Pharmaceuticals, Inc.

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc.

ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - SBPH, VAR, JCAP, GLIBA

Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs

Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results

NEW ORLEANS, Aug. 6, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

SPRING BANK PARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Spring Bank Pharmaceuticals, Inc. - SBPH

NEW YORK, Aug. 5, 2020 /PRNewswire/ --Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Spring Bank Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Spring Bank Pharmaceuticals, Inc. - SBPH

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Spring Bank Pharmaceuticals, Inc.

SPRING BANK ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SBPH and Encourages Investors to Contact the Firm

NEW YORK, July 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in.

Spring Bank Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Spring Bank Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the proposed merger of the company with F-star Therapeutics, Limited.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Spring Bank Pharmaceuticals, Inc.

New York, New York--(Newsfile Corp. - July 30, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/60827_8954c78214f649b7_001full.jpgTo: All Persons or Entities

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Spring Bank Pharmaceuticals, Inc. and F-Star Therapeutics, Limited is Fair to SBPH Shareholders

HOPKINTON, Mass. and CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July  29, 2020  (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, and F-star Therapeutics, Limited (“F-star”), a privately-held clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announced that the companies have entered into a definitive share exchange agreement pursuant to which Spring Bank will, subject to stockholder approval, acquire all of the outstanding share capital of F-star in exchange for newly issued shares of Spring Bank in an all-stock transaction. The combined company, operating under the name F-star Therapeutics, Inc., will advance its immuno-oncology pipeline of multiple tetravalent bispecific antibody programs, as well as Spring Bank’s STING (STimulator of INterferon Gene) agonist, SB 11285, currently in a Phase 1/2 clinical trial.

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies

-      Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®)

Spring Bank Advances IV SB 11285 Clinical Program

HOPKINTON, Mass., April  02, 2020  (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today provided an update on the company’s business operations in response to and as a result of the global COVID-19 pandemic.

Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic

Spring Bank Pharmaceuticals Inc. [s; sbph] said Wednesday it is scrapping the development of inarigivir soproxil, a treatment for chronic hepatitis B virus, after a patient died during a phase 2 trial.

Spring Bank Pharma to end development of treatment for chronic HBV after patient death

HOPKINTON, Mass., Jan.  29, 2020  (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has discontinued development of inarigivir soproxil, which was in Phase 2 development for the treatment of chronic hepatitis B virus (HBV). This decision was made in the interest of patient safety based on the occurrence of unexpected serious adverse events, including one patient death, in Spring Bank’s Phase 2b CATALYST trial.

Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV

Chuy's Hlds

Customers Bancorp

Delek Logistics Partners

Ultra Clean

The upbeat sentiments prevailing in Wall Street make investment in small caps stocks attractive for 2020, here's why.

5 Must-Buy Small Caps for Big Returns in 2020

Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.

Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down

Spring Bank Pharmaceutical Inc.'s shares  slid 17% in premarket trade Thursday, after the clinical-stage biopharma company said it has stopped dosing patients in a trial of a treatment for chronic hepatitis B virus, or HBV.

Spring Bank Pharma shares slide 17% premarket after it halts trial of treatment for hepatitis B virus

HOPKINTON, Mass., Dec.  26, 2019  (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that the company has stopped dosing and enrolling patients in its Phase 2b CATALYST trials, which are examining the use of inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus (HBV). In addition, the company has stopped dosing and enrollment in all other studies of inarigivir in subjects with chronic HBV.

Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program

As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals.

News for Spring Bank Pharmaceuticals Stock (SBPH)